|
|
||||||||
Intestinal Disease Research Programme, Departments of 1 Medicine and 2 Pathology, McMaster University, Hamilton, Ontario, Canada L8N 3Z5
| |
ABSTRACT |
|---|
|
|
|---|
Specific in vivo T cell activation initiated by treatment with anti-CD3 antibodies leads to diarrhea and structural damage of the intestinal mucosa. In this study, the effect of T cell-induced mucosal damage on jejunal epithelial ion transport, muscle contractility, and neuronal ACh release was assessed in Ussing chambers, organ baths, and a specialized perfusion apparatus, respectively. Time-matched control mice received hamster serum containing irrelevant antibodies. Jejunal segments from anti-CD3-treated mice displayed a significantly elevated epithelial baseline short-circuit current (which indicates increased ion transport) and a concomitant reduction in responsiveness to prosecretory stimuli (nerve stimulation, carbachol, and forskolin). Longitudinal smooth muscle displayed altered spontaneous contractile activity, length-tension relationships, and carbachol-stimulated contraction in tissues excised from mice 20 and 40 h posttreatment. Anti-CD3 treatment did not affect stimulated ACh release from myenteric plexus neurons. We conclude that specific T cell activation via anti-CD3 antibody results in dramatic alterations in jejunal epithelial and smooth muscle function. Such T cell-induced changes in intestinal function may contribute to the symptomatology of T cell-mediated enteropathies, including graft-versus-host disease, celiac disease, and idiopathic inflammatory bowel disease.
epithelium; smooth muscle
| |
INTRODUCTION |
|---|
|
|
|---|
EXAGGERATED OR INAPPROPRIATELY regulated immune events can result in significant alterations in intestinal structure and function. T cells have been implicated as a pivotal cell type in the mediation of intestinal pathophysiology (10, 21). For instance, intestinal mucosa resected from patients with inflammatory bowel disease (4) and celiac disease (23) have increased numbers of activated T cells. Experimental models of graft-versus-host disease, helminth infections in rodents, and analysis of human fetal intestinal explants have demonstrated that T cell activation alters gut structure (22, 35, 40). In contrast, there is significantly less information on the ability of T cells to regulate the physiological functions of the intestine.
Patients receiving immunosuppressive therapy with anti-CD3 antibody
often develop a syndrome consisting of fever, headaches, and diarrhea
(30). Similarly, administration of anti-CD3 antibodies to mice results
in a "cytokine release syndrome" that is characterized by T cell
activation, i.e., increased serum interleukin (IL)-2, tumor necrosis
factor (TNF)-
, and interferon (IFN)-
, and clinical diarrhea
(13-15). We have recently reported that in vitro coculture of
anti-CD3-activated peripheral blood mononuclear cells with a model
human Cl
-secretory
epithelial cell line (T84) evokes significant increases in epithelial
permeability and a diminished capacity of the T84 monolayer to respond
to prosecretory stimuli (27). In this in vitro system no change in
baseline ion transport was detected. These observations indicate that
specific T cell activation through the T cell receptor/CD3 complex
alters epithelial physiology. However, the gut is a multifunctional
organ and diarrhea is the net outcome of altered epithelial ion
transport (secretion or absorption) creating driving forces for
directed water movement, increased permeability, and/or
dysregulated peristalsis. In addition, altered neuronal and stromal
cell influences on the normal homeostatic responses can result in
abnormal water movement and muscle contractility. Caution must be
employed when extrapolating from in vitro data to the in vivo
situation. There are a number of examples that illustrate how the in
vivo situation can be very different from that predicted by in vitro
experimental results. For example, the absence of
CD4+ T cells did not prevent major
histocompatibility complex class II-restricted T
cell responses (32) and the effects of in vivo endotoxin on colonic
fluid and electrolyte handling were different than those seen during in
vitro experiments (5). Thus, although in vitro models are instructive,
they must be supplemented by integrated in vivo observations.
Here we used an integrated, multisystem approach to define the enteric physiological ramifications of specific in vivo T cell activation. Changes in gut morphology, neuronal activity, epithelial electrolyte transport, and muscle contractility in response to specific in vivo T cell activation via treatment with anti-CD3 antibodies were examined. Our findings illustrate that the jejunum from mice treated with anti-CD3 display increased epithelial ion transport and altered spontaneous muscle activity and increased contractility of the longitudinal smooth muscle. This supports the postulate that in vivo T cell activation significantly alters gut function at a number of levels.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Mice
BALB/c mice (female, 6-8 wk old; Charles River) received a single intraperitoneal injection of 50 µg of the monoclonal anti-CD3 antibody 145-2C11 prepared from hamster hybridoma cells (kindly provided by Dr. J. Bluestone, University of Chicago) in 0.5 ml of PBS. Control animals received an equal amount of nonspecific hamster IgG (HIgG) (Rockland, Gilbertsville, PA). Mice were housed in microfilter-isolated cages, allowed free access to autoclaved food and water, and were killed by cervical dislocation at various times after treatment. This study was approved by the McMaster University Animal Care Committee and conforms to the guidelines of the Canadian Council on Animal Care.Histological Studies
Portions of jejunum were excised 1 cm distal to the ligament of Trietz and were immediately immersion fixed in 10% neutral-buffered Formalin. The tissue segments were then dehydrated though graded alcohols, cleared in xylene, and embedded in paraffin wax. Sections (3 µm) were cut perpendicular to the longitudinal axis of the villi, collected on coded slides, and stained with hematoxylin and eosin. Sections were examined for changes in mucosal architecture and evidence of neutrophil infiltrate.Myeloperoxidase Determination
Tissues for assessment of myeloperoxidase (MPO) content were snap-frozen in liquid nitrogen and stored at
70°C. MPO was
measured as previously described (3). MPO levels were determined as units of MPO per milligram of tissue wet weight, with one unit of MPO
representing the amount of enzyme able to convert 1 mol of
H2O2
to water in 1 min at room temperature.
Immune Activation
TNF-
levels. Serum samples were
taken from mice killed at various time points after anti-CD3 treatment.
TNF-
levels were measured in the serum using a commercial ELISA (R&D
Systems, Minneapolis, MN). Each sample was tested in duplicate, and the
concentrations were determined from a standard curve generated in each
assay. The sensitivity of the TNF-
ELISA was 5 pg/ml.
Mucosal lymphocyte activation. Intraepithelial lymphocytes (IEL) were isolated from groups of five mice and pooled as previously described (9). Briefly, the small intestines were flushed with PBS, Peyer's patches were excised, and IEL was released from the remaining tissue by incubation in Ca2+-Mg2+-free Hank's medium (supplemented with 0.1 mM EDTA) for 30 min at 37°C with continuous stirring. IEL were purified by filtration through nylon wool columns followed by density centrifugation (600 g for 25 min) on a discontinuous Percoll gradient [40 and 70% (vol/vol)]. The resultant IEL population was >95% viable and 80-90% CD3+ as determined by flow cytometry analysis performed as previously described (9). Contamination by lamina propria lymphocytes, as assessed by measuring surface immunoglobulin-positive cells, accounted for <10% of the preparation (9) and morphological assessment revealed <5% contamination by epithelial cells.
Mice received an injection of 1.5 mg ip of bromodeoxyuridine (BrdU)
4-6 h before autopsy. The isolated IEL and spleen cells were fixed
in 70% ethanol at
20°C for 60 min and permeabilized, and
the nuclear DNA was denatured into single-stranded molecules with 2 N
HCl in 0.5% (vol/vol) Triton X-100 (Sigma, St Louis, MO) solution for
30 min at room temperature. Excess HCl was first neutralized with 0.1 M
Na2B4O7
(pH 8.5) and then washed in 0.5% Tween 20-1.0% BSA-PBS
(Tween-BSA-PBS) solution (pH 7.4). Cells were immunoreacted with
FITC-conjugated mouse anti-BrdU monoclonal antibody (Becton Dickinson)
or FITC-conjugated isotype control antibody (both diluted 1:20 in
Tween-BSA-PBS) for 30 min at room temperature. After further washing in
Tween-BSA-PBS, BrdU positivity was quantified by flow cytometry
analysis (10,000 events were counted/sample) (9). BrdU positivity
identifies cells that were activated into S phase of the cell cycle
during the 4-6 h of exposure to BrdU.
Enteric Functional Changes
Epithelial ion transport. Assessment of murine jejunal epithelial ion transport was performed as previously described (25). Briefly, beginning 2 cm distal to the ligament of Trietz, two adjacent portions of full-thickness jejunum (~2.5 cm long) were excised and mounted in Ussing chambers (exposed surface area = 0.6 cm2). The jejunum was bathed in 10 ml of oxygenated Krebs buffer (in mM: 115.0 NaCl, 8.0 KCl, 1.25 CaCl2, 1.2 MgCl2, 2.0 KH2PO4, 25.0 NaHCO3; pH 7.35 ± 0.02). The buffers were maintained at 37°C by a surrounding heated water jacket and circulated by a CO2-O2 gas lift. Glucose (10 mM) was added to the buffer on the serosal side of the tissue and was osmotically balanced by the addition of 10 mM mannitol to the luminal buffer.BASELINE SHORT-CIRCUIT CURRENT. Each tissue was short circuited at zero volts using an automated voltage clamp (WPI Instruments, Narco Scientific, Mississauga, ON, Canada), and the short-circuit current (Isc; in µA/cm2) was continuously monitored as an indication of net ion transport. At 15-min intervals the voltage-clamp mode was removed, and the spontaneous potential difference (PD; in mV) of the tissues was measured. Tissue ionic conductance (G; in mS/cm2) was then calculated using Ohm's law. Baseline Isc and G were measured after a 20-min equilibration period.
STIMULATED ISC. Increases in Isc were evoked by transmural electrical stimulation of the enteric nerves (ETS at 10 Hz, 10 mA, 0.5 ms for a total time of 5 s) (25) and then by sequential addition of the cholinergic agonist carbachol (10
4 M) and the adenylate
cyclase-activating agent forskolin
(10
5 M) (both from Sigma)
For the response to secretagogues, tissues were first exposed to
carbachol, which caused a transient increase in
Isc. Fifteen
minutes later, when
Isc had returned
to baseline, forskolin was added to the serosal side of the same
Ussing-chambered jejunal tissue and this evoked a sustained elevation
of Isc.
Epithelial responsiveness was defined as the maximum increase in
Isc to occur within 5 min of nerve stimulation or exposure to the secretagogues. These agents and their maximal doses were chosen because they elicit
predominantly an active Cl
secretion via intracellular Ca2+
and cAMP, respectively (1), and for direct comparison without previous
in vitro investigation (27).
Smooth muscle contractility. Isometric
tension and spontaneous contractile activity were recorded from muscles
strips as previously described for mouse intestine (37). A 1-cm portion
of jejunum was removed, oriented along its longitudinal axis, and
placed in oxygenated (95%
O2-5%
CO2) Krebs solution. Tissue was
aligned vertically with one end anchored to the base of the 20-ml bath and the other attached to a Grass FT03 force transducer. Responses were
measured isometrically and recorded on a Grass 7D polygraph. The
frequency and amplitude of spontaneous contractile activity was
determined after a 30-min equilibration period, with 300 mg of tension.
Intestinal tissues (
3/mouse) were stretched along their longitudinal
axis by applying various tension settings (0-2,000 mg of weight),
allowed to equilibrate for 10 min, and then contracted by exposure to
carbachol (10
6 M). After
stimulation, tissues were washed twice with Krebs, moved to the next
tension setting, and reexposed to carbachol. At the end of each
experiment, the tissues were blot dried and weighed. Optimal tension
was determined by the degree of applied tension that produced a maximum
contraction in response to carbachol. Tissue weight and length at the
optimal tension was used to determine cross sectional area of tissue,
as previously described (39). Dose-response experiments were also
conducted for carbachol
(10
4-10
9
M), in which each tissue was immediately stretched to the optimal tension as determined by the length-tension experiments.
The force generated in the length-tension and dose-response curves is
expressed in milligrams and normalized for cross sectional area (CSA)
as determined by the following equation: CSA
(mm2) = tissue wet weight
(mg)/[tissue length (mm) × density
(mg/mm3)], where density
of smooth muscle was presumed to be 1.05 mg/mm3 (39). The concentration of
the agonist required to induce a 50% maximum response
(ED50) was obtained by a probit
analysis of Litchfield and Wilcoxon for each tissue, and a mean
ED50 value was calculated for each mouse.
Neurotransmitter release from the myenteric
plexus. Jejunal longitudinal muscle-myenteric plexus
(LMMP) preparations were incubated for 60 min in oxygenated Krebs
buffer containing
[3H]choline (5 µCi).
After washing, the tissues were mounted in a superfusion chamber,
subjected to an electrical field stimulation; 30 V, 0.5 ms, 10 Hz for
60 s and subsequently to exposure to 50 mM KCl for 6 min. The evoked
release of [3H]choline
was determined as the difference between total
[3H]choline released
during stimulation and the calculated spontaneous release of
[3H]choline from the
tissue. This value was expressed as a fractional release unit (fru) and
was calculated as a percentage of total [3H]choline present in
the tissue at the time of stimulation. This assay for
[3H]choline release
was validated by our laboratory (7).
Data Presentation and Statistical Analysis
Data are presented as means ± SE, and n values represent the number of mice per group. Student's t-test was used for statistical comparisons between two groups, and a one-way ANOVA followed by post hoc comparisons (Newman-Kuels test) was used to examine data from three or more experimental groups. A statistically significant difference was accepted at P < 0.05.| |
RESULTS |
|---|
|
|
|---|
Jejunal Morphology
Mice treated with anti-CD3 were noticeably lethargic, developed a hunched posture, piloerection, and diarrhea, as shown by discoloration of the perianal area, within 4 h of treatment. This confirms previously reported effects of murine anti-CD3 treatment (9). Macroscopically, there was fluid accumulation in the small bowel of anti-CD3-treated mice, especially at 20 h postinjection. Histological examination of jejunal sections from anti-CD3-treated mice revealed dramatic changes in jejunal morphology. Twenty hours after treatment, villus height was reduced and the crypts appeared to have degenerated with varying degrees of edema and cell death, as evidenced by obvious pycnotic nuclei (Fig. 1D). These events were further exaggerated by 40 h posttreatment, when the villi were significantly stunted and normal crypts were virtually unrecognizable (Fig. 1, E and F). The disorganized mucosa was littered with pycnotic nuclei, and released Paneth cell granules were often prominent. These changes in jejunal structure had resolved by 120 h post-anti-CD3 treatment. During this time course, there was no obvious jejunal neutrophil infiltration in response to anti-CD3. Corroborating this finding, tissue MPO levels were not elevated by anti-CD3 treatment: control tissues (HIgG treated) = 1.8 ± 0.2; 20 h anti-CD3 = 0.8 ± 0.3; control = 2.2 ± 0.5 units; 40 h anti-CD3 = 0.7 ± 0.2 units of MPO/mg tissue (n = 5 or 6). Anti-CD3 treatment did not cause any gross histological damage to either the circular or longitudinal muscle layers or to the myenteric plexus.
|
Immune Activation
TNF-
production.
Anti-CD3-treated mice showed an increase in serum TNF-
that was
maximal 30 min after injection and declined gradually thereafter. At 20 h after treatment, no significant difference was detectable between the
anti-CD3-treated and the control group (Table
1).
|
IEL BrdU incorporation. Table
2 shows the changes in the proportion of IEL and spleen
cells with BrdU incorporation in mice treated with anti-CD3 antibody
compared with control animals. The statistically significant increase
in the proportion of IEL positive for BrdU suggests that IEL were
activated into S phase after in vivo anti-CD3 stimulation, whereas
there was minimal incorporation of BrdU in spleen cells.
|
Enteric Functional Changes
Epithelial function. When examined in Ussing chambers, jejunal segments from anti-CD3-treated mice displayed a statistically significant increase in baseline Isc, reflecting an increase in active ion transport (Fig. 2). This change in baseline electrolyte transport was self-limiting and was not observed in tissues from mice 120 h after a single anti-CD3 injection. In contrast to the increase in basal ion transport tone, stimulated ion transport was significantly reduced in tissues from anti-CD3-treated mice. In response to electrical nerve stimulation, exogenous carbachol, (10
4 M) or forskolin
(10
5 M), tissues from
anti-CD3-treated mice showed diminished
Isc responses
compared with jejunal segments obtained from control mice (Table
3). This diminished ion transport responsiveness was not
evident 120 h after treatment. Transepithelial ionic conductance, indicating the barrier to passive ion movement, was not significantly altered at any time after anti-CD3 exposure (Table 3).
|
|
Muscle function. Because significant
changes in jejunal epithelial ion transport were evident at 20 and 40 h
posttreatment, we focused our subsequent studies on muscular activity
on these two times. Muscle strips from control HIgG-treated mice
exhibited a constant frequency and amplitude of contraction (Table
4). Twenty hours after anti-CD3 treatment, there was an
increase in frequency of contraction and a reduction in amplitude
(Table 4 and Fig. 3). By 40 h post-anti-CD3 treatment,
the frequency of smooth muscle contraction had returned to normal, but
the amplitude of contraction remained depressed (Table
4).
|
|
Significant differences were observed in the length-passive tension
characteristics of the longitudinal smooth muscle, particularly at the
lower tension settings, in tissues from mice 20 and 40 h after anti-CD3
treatment. Figure 4 shows the tension generated with
carbachol at different applied tensions in tissues taken from mice 20 h
after anti-CD3 treatment. The results show a significant increase in
contraction from 0 to 750 mg of applied tension after stimulation with
10
6 M of carbachol. Jejunal
tissues from mice treated 40 h previously with anti-CD3 showed a
carbachol-induced contractile response that was still significantly
greater than that in control tissues but was slightly reduced compared
with 20 h CD3-treated animals (data not shown). However, although the
absolute response was different between test and control animals,
muscle preparations from all groups generated the maximum increase in
tension in response to 500 mg of applied tension.
|
Muscle preparations from anti-CD3-treated mice had a significant
increase in contraction generated in response to concentrations of
carbachol (10
6 M; Fig.
5). HIgG-treated mice maintained the same
ED50 values at 20 h (1.43 × 10
5 ± 4.81 × 10
6 M) as at 40 h (1.43 × 10
5 ± 1.63 × 10
6 M). No
significant difference in ED50
values was observed between anti-CD3-treated mice at 20 h (1.34 × 10
5 ± 1.62 × 10
6 M) and 40 h (9.02 × 10
6 ± 3.21 × 10
6 M) compared
with controls. As with the length-tension relationship, mice treated 40 h previously with anti-CD3 showed increased jejunal carbachol
(>10
6 M)-evoked
contraction compared with control tissues but were attenuated compared
with their 20-h anti-CD3-treated counterparts (Fig. 5).
|
Neuronal function. Examination of stimulated [3H]choline release (as indicative of ACh release) from the LMMP preparations revealed no significant differences between mice treated with anti-CD3 and their respective time-matched controls. LMMPs from HIgG-treated mice had consistent release of radiolabeled ACh: 1.9 ± 0.2 and 1.9 ± 0.3 fru for 20 and 40 h time-matched controls, respectively. Anti-CD3-treated mice displayed no consistent deviation from control values: 20 h post-anti-CD3 = 1.8 ± 0.3 fru and 40 h anti-CD3 = 1.9 ± 0.3 fru. The response of anti-CD3-treated mice intestine to KCl stimulation was no different from control mice intestine (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
We report the results of an integrated study that examines the effects of specific in vivo T cell activation on several parameters of the physiological function of the small intestine. Our findings show that in vivo T cell activation via anti-CD3 crosslinking of the T cell receptor results in 1) increased jejunal epithelial baseline Isc; 2) diminished ion transport responses to prosecretory stimuli; and 3) altered spontaneous and carbachol-evoked (i.e., cholinergic) muscle contraction. In contrast, the stimulated release of ACh from myenteric neuronal plexus-longitudinal muscle preparations was not affected by in vivo anti-CD3 treatment.
Mice treated with a single intraperitoneal dose of the T
cell-activating antibody anti-CD3 develop a clinical syndrome that includes severe self-limited diarrhea (14). Our present findings confirm previously documented structural changes of the small intestine
associated with this syndrome: reduction in villus height and
disruption of crypt structures (Fig. 1) (29). These changes are similar
to those seen in intestinal diseases associated with T cell activation
(4, 21, 23, 29). To document immune cell activation we showed that
anti-CD3 treatment is associated with an increase in serum levels of
TNF-
and with activation of local lymphocytes, as evidenced by the
increased uptake of BrdU into IEL. Furthermore, we have previously
shown that the anti-CD3 effect on gut architecture is dependent on T
cells expressing the
/
T cell receptor, because mice lacking T
cells (i.e., SCID mice,
/
T cell receptor knockout mice) fail to
respond to anti-CD3 (29). Therefore this model allows us to determine
the changes in epithelial and smooth muscle function that result from T
cell activation and may contribute to the clinical syndrome of diarrhea associated with mucosal damage.
In response to anti-CD3 treatment, jejunal baseline Isc was increased about three- to fourfold 20-72 h after treatment. An increase in intestinal electrolyte transport is often indicative of electrogenic chloride transport into the gut lumen or, alternatively, enhanced cation (sodium) absorption (1). The in vivo observation of fluid accumulation in the intestinal lumen after anti-CD3 treatment in conjunction with increased basal Isc supports the contention that direct T cell activation results in a prosecretory or a malabsorptive diarrheal event. Therefore, in addition to neuroendocrine/immune factors that regulate water movement, specific T cell activation is also a contributing factor that may be relevant to the diarrhea experienced by patients with graft-versus-host disease, celiac disease, and other idiopathic disorders, such as inflammatory bowel disease.
The in vivo model also allows us to examine the changes in physiological function of a defined compartment (e.g., epithelium) in the context of changes in other elements of the small intestine. For example, in our in vitro coculture studies, we did not observe an increase in baseline epithelial (T84) Isc after anti-CD3 activation of peripheral blood mononuclear cells (27). This indicates that other cells, such as fibroblasts (31), that are absent in the in vitro model likely modulate epithelial Isc after T cell activation. This illustrates the value of the integrative approach and the need to juxtapose in vitro and in vivo models when examining the influence of the immune system on the physiological function of the intestine.
In contrast to the changes in baseline
Isc, stimulated
Isc responses
were consistently reduced in jejunal segments from anti-CD3-treated mice. These changes correlate temporally with the alterations in gut
morphology (i.e., villus atrophy, loss of crypt definition). This is
similar to the results of our in vitro studies (27-29) as well as
studies on gut segments from animals with enteric infections and
tissues from patients with inflammatory bowel disease (19, 20, 25). Several scenarios could explain these changes in ion transport
properties of the intestine. First, the reduced stimulated
Isc responses may
be a consequence of the increased basal
Isc. Basal ion
transport is governed to a large extent by the enteric nervous system
(8), thus it is feasible that tissues from anti-CD3-treated mice that
display increased baseline
Isc are somewhat
tachyphylactic to neurotransmitters (i.e., electrical nerve stimulation
and the cholinergic agonist carbachol). Second, decreased
Isc responses
could be due to epithelial cell loss and/or derangement of
normal crypt architecture, because the crypt region is the predominant
site of ion secretion. In support of this is the finding that
chemically 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats
causes major tissue damage and a concomitant loss of
Na+ and
Cl
absorption (2). Third,
the release of mediators such as arachidonic acid metabolites, reactive
oxygen species, and cytokines from activated T cells or from other
mucosal cells in response to T cell activation could directly modulate
epithelial ion transport processes. In this context, in vitro studies
with the T84 Cl
secretory
epithelial cell line have shown that exposure to IFN-
or IL-4 can
result in diminished secretory responses to forskolin, carbachol, and
the neuropeptide vasoactive intestinal peptide (18, 27, 34, 41).
Additionally, we have shown that T cell activation by a bacteria
superantigen resulted in reduced T84 ion transport responses and that
IFN-
and TNF-
were important mediators in this in vitro system
(28). Indeed, both IFN-
and TNF-
have been implicated in the
mediation of anti-CD3-induced diarrhea (26); however, our studies in
knockout mice indicate that anti-CD3-induced disruption of normal gut
structure can occur independent of TNF-
(29). Although the precise
mechanism underlying the changes in ion transport in this
anti-CD3-induced enteropathy remains to be elucidated, the present
study illustrates the capacity of T cells to regulate directed water
movement in the gut.
Transepithelial ion conductance reflects the barrier properties of the gut to passive ion flux. Tissue conductance was not significantly altered after anti-CD3 treatment, suggesting unperturbed gut permeability. This finding does not correlate with the dramatic disruption of gut architecture and is in stark contrast to the dramatic loss of the barrier function of model epithelial monolayers after coculture with activated immune cells or recombinant cytokines (33, 41). It is possible that opposing changes in the attendant muscle or serosal tissue layers could offset an increase in epithelial permeability. Indeed, studies with whole-thickness tissues (as conducted here) must also account for the barrier effect of the muscle layers and the outer serosa, which do not confound studies using muscle-stripped intestinal segments or defined pure epithelial cell lines. Moreover, ionic conductance does not necessarily reflect the permeability characteristics of the gut to larger molecules (17, 36). Thus ex vivo flux studies with larger marker molecules and in vivo lumen-to-blood probe recovery studies are required to further explore the ability of anti-CD3-activated T cells to affect the barrier function of the epithelium.
Alterations in the propulsive function of the intestine can also contribute to diarrheal illnesses. Assessment of gut tissue from parasitized rodents has implicated T cells in the regulation of muscle activity (6). This may be mediated by cytokines such as IL-4 that can influence smooth muscle contractility (38). Here we report a significant change in the spontaneous contractile activity (increased frequency and decreased amplitude) of longitudinal smooth muscle preparations of the jejunum 20 and 40 h after anti-CD3 injection. A functional correlate of this could be the loss of the coordinated peristaltic wave of contraction within the small bowel. We also found that anti-CD3 treatment caused a significant increase in carbachol-elicited contractile responses. Analysis of the length-tension relationship revealed that maximum muscle contraction occurred at 500 mg of tension for anti-CD3-treated and control mice. This implied that no major structural alterations had occurred in the smooth muscle tissue and this is supported by the normal histological appearance of the muscle layers (Fig. 1). Dose-response curves illustrated that jejunal segments from anti-CD3-treated mice were hyperresponsive to carbachol; however, the unaltered ED50 value suggests that the affinity of cholinergic receptors was not affected by anti-CD3 T cell activation. This suggests that the mechanism responsible for this increase in contraction to carbachol is in postreceptor signal transduction, such as calcium use (16). We observed that stimulated ACh release from LMMP preparations was unaffected by in vivo anti-CD3 treatment, providing additional support for the postulate that the increase in contractility is unlikely to be attributable to altered enteric neuronal activity.
Previous studies have correlated increases in smooth muscle contractility with increased propulsive activity of the intestine (11, 12). Although a formal examination of propulsion was not conducted in this study, we suggest that the perturbed muscle contraction noted here is a contributing factor to the diarrhea associated with T cell activation. In addition, it is reasonable to suggest that the changes in spontaneous contractile activity may be related to effects on intermediate cells that regulate muscle activity, such as the putative pacemaker cells, the interstitial cells of Cajal (24).
To determine if anti-CD3 T cell activation induced the influx of granulocytes commonly seen during enteric infections, MPO activity was measured in tissue homogenates. We found no evidence for neutrophil infiltration in the intestine during the course of the enteropathy (29). Thus our data indicate that T cell activation results in rapid and distinct changes in jejunal structure and function in the absence of a classical marker of acute inflammation, the neutrophil.
In conclusion, we have illustrated that specific in vivo T cell activation results in altered epithelial ion transport and smooth muscle contractility that is not entirely predicted by in vitro studies using coculture systems or by studies of enteric infection-induced intestinal inflammation. These findings point to the value of in vivo studies where morphological and functional abnormalities resulting from changes in a number of systems can interact. Thus in vivo T cell activation leads to a small bowel enteropathy characterized by morphological and functional abnormalities reminiscent of those seen in graft-versus-host disease, celiac disease, and to some degree, inflammatory bowel disease. This model allows us to address the issue of defining the cellular and molecular mechanisms involved in the mediation of T cell regulation of enteric epithelial and smooth muscle function and gut homeostasis in general.
Perspectives
The traditional approach to understanding biological systems, where cells, mediators, and processes are considered as isolated distinct groups, is rapidly being replaced by a research approach where integration is emphasized. Although this seems intuitive when examining dynamic, multifunctional organs such as the gut, many studies focus on a single physiological process. In the present assessment of a murine T cell-driven enteropathy we examined the functional changes in a variety of target cells, i.e., epithelial cell, muscle cell, neuron, and granulocytes (as indicated by MPO activity). The changes in the behavior of these cells can independently, or cooperatively, result in abnormal gut function and, in this instance, diarrhea. In our in vivo model of T cell-mediated intestinal damage we have shown that epithelial electrolyte transport irregularities and altered muscle function without altered neurotransmitter release, contributed to the clinical syndrome of diarrhea. The precise role(s) of T cells, subsets of T cells, and chemical mediators released in response to specific T cell activation in immune-mediated gut dysfunction remain to be elucidated. Moreover, the broad, integrated research strategy employed here aptly illustrates the advantage of concomitant assessment of the activity of a variety of cell types when attempting to dissect physiological pathways and understand pathophysiological mechanisms.| |
ACKNOWLEDGEMENTS |
|---|
N. Radojevic and D. M. McKay contributed equally to this work.
| |
FOOTNOTES |
|---|
We thank D. Steele-Norwood, P. Blennerhassett, and M. Benjamin for technical assistance.
This work was supported by research grants from the Medical Research Council of Canada to D. M. McKay, S. M. Collins, and K. Croitoru. M. Merger holds a fellowship from the Deutsche Forschungsgemeinschaft (Grant Me 1403/1-1).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: K. Croitoru, MDCM FRCP(C), Intestinal Disease Research Program, HSC-4W8, Dept. of Medicine, McMaster Univ., 1200 Main St. West, Hamilton, Ontario, Canada L8N 3Z5 (E-mail: croitoru{at}fhs.McMaster.ca).
Received 22 June 1998; accepted in final form 30 November 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Barrett, K. E.,
and
K. Dharmsathaphorn.
Secretion and absorption: small intestine and colon.
In: Textbook of Gastroenterology, edited by T. Yamada. Philadelphia, PA: Lippincott, 1991, p. 265-294.
2.
Bell, C. J.,
D. G. Gall,
and
J. L. Wallace.
Disruption of colonic electrolyte transport in experimental colitis.
Am. J. Physiol.
268 (Gastrointest. Liver Physiol. 31):
G622-G630,
1995
3.
Boughton-Smith, N.,
J. L. Wallace,
and
B. J. R. Whittle.
Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease.
Agents Actions
25:
115-123,
1988[Medline].
4.
Burgio, V. L.,
S. Fais,
M. Boirivant,
A. Perrone,
and
F. Pallone.
Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease.
Gastroenterology
109:
1029-1038,
1995[Medline].
5.
Ciancio, M. J.,
L. Vitiritti,
A. Dhar,
and
E. B. Chang.
Endotoxin-induced alterations in rat colonic water and electrolyte transport.
Gastroenterology
103:
1437-1443,
1992[Medline].
6.
Collins, S. M.
Immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders.
Gastroenterology
111:
1683-1699,
1996[Medline].
7.
Collins, S. M.,
P. A. Blennerhassett,
M. G. Blennerhassett,
and
D. L. Vermillion.
Impaired acetylcholine release from the myenteric plexus of Trichinella-infected rats.
Am. J. Physiol.
257 (Gastrointest. Liver Physiol. 20):
G898-G903,
1989
8.
Cooke, H. J.
Neuroimmune signaling in regulation of intestinal ion transport.
Am. J. Physiol.
266 (Gastrointest. Liver Physiol. 29):
G167-G178,
1994
9.
Croitoru, K.,
J. Bienenstock,
and
P. B. Ernst.
Phenotypic and functional assessment of intraepithelial lymphocytes bearing a "forbidden"
/
T cell receptor.
Int. Immunol.
6:
1467-1473,
1994
10.
Elson, C. O.,
R. B. Sartor,
G. S. Tennyson,
and
R. H. Riddell.
Experimental models of inflammatory bowel disease.
Gastroenterology
109:
1344-1367,
1995[Medline].
11.
Farmer, S. G.
Propulsive activity of the rat small intestine during infection with the nematode Nippostrongylus brasiliensis.
Parasite Immunol.
3:
227-234,
1981[Medline].
12.
Farmer, S. G.,
J. M. Brown,
and
D. Pollock.
Increased responsiveness of intestinal and vascular smooth muscle to agonists in rats infected with Nippostrongylus brasiliensis.
Arch. Int. Pharmacodyn. Ther.
263:
217-227,
1983[Medline].
13.
Ferran, C.,
M. Dy,
K. Sheehan,
S. Merite,
R. Schreiber,
P. Landais,
G. Grau,
J. Bluestone,
J. F. Bach,
and
L. Chatenoud.
Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release.
Clin. Exp. Immunol.
86:
537-543,
1991[Medline].
14.
Ferran, C.,
K. Sheehan,
M. Dy,
R. Schreiber,
S. Merite,
P. Landais,
L. H. Noel,
G. Grau,
J. Bluestone,
and
J. F. Bach.
Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.
Eur. J. Immunol.
20:
509-515,
1990[Medline].
15.
Finck, B. K.,
C. M. Yung,
N. L. Carteron,
and
D. Wofsy.
The role of T cell subsets in the response to anti-CD3 monoclonal antibodies.
Clin. Immunol. Immunopathol.
65:
234-241,
1992[Medline].
16.
Fox-Robichaud, A. E.,
and
S. M. Collins.
Altered calcium handling properties of jejunal smooth muscle from nematode infected rats.
Gastroenterology
91:
1462-1469,
1986[Medline].
17.
Hollander, D.
The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease.
Scand. J. Gastroenterol.
27:
721-726,
1992[Medline].
18.
Holmgren, J.,
J. Fryklund,
and
H. Larsson.
Gamma-interferon-mediated down-regulation of electrolyte secretion by intestinal epithelial cells: a local immune mechanism?
Scand. J. Immunol.
30:
499-503,
1989[Medline].
19.
Hubel, K. A.,
and
K. S. Renquist.
Ion transport in normal and inflamed human jejunum in vitro: changes with electrical field stimulation and theophylline.
Dig. Dis. Sci.
35:
815-820,
1990[Medline].
20.
Kachur, J. F.,
A. Keshavarzian,
R. Sundaresan,
M. Moria,
R. Walsh,
M. M. de las Alas,
and
T. S. Ganginella.
Colitis reduces short-circuit current response to inflammatory mediators in rat colonic mucosa.
Inflammation
19:
245-259,
1995[Medline].
21.
MacDermott, R. P.
Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease.
Med. Clin. North Am.
78:
1207-1231,
1994[Medline].
22.
MacDonald, T. T.,
and
J. Spencer.
Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine.
J. Exp. Med.
167:
1341-1349,
1988
23.
Maiuri, L.,
A. Picarelli,
M. Boirivant,
S. Coletta,
M. Mazzilli,
M. De Vincenzi,
M. Londei,
and
S. Auricchio.
Definition of the initial immunologic modifications upon in vitro gliadin challenge in the small intestine of celiac patients.
Gastroenterology
110:
1368-1378,
1996[Medline].
24.
Malysz, J.,
L. Thuneberg,
H. B. Mikkelesen,
and
J. D. Huizinga.
Action potential generation in the small intestine of W mutant mice that lack interstitial cells of Cajal.
Am. J. Physiol.
271 (Gastrointest. Liver Physiol. 34):
G387-G399,
1996
25.
Masson, S. D.,
D. M. McKay,
R. H. Stead,
A. Agro,
A. Stanisz,
and
M. H. Perdue.
Nippostrongylus brasiliensus infection causes neuronal abnormalities and altered neurally regulated ion secretion in rat jejunum.
Parasitology
113:
173-182,
1996.
26.
Matthys, P.,
C. Dillen,
P. Proost,
H. Heremans,
J. Van Damme,
and
A. Billiau.
Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels.
Eur. J. Immunol.
23:
2209-2216,
1993[Medline].
27.
McKay, D. M.,
K. Croitoru,
and
M. H. Perdue.
T cell-monocyte interactions regulate epithelial physiology in a co-culture model of inflammation.
Am. J. Physiol.
270 (Cell Physiol. 39):
C418-C428,
1996
28.
McKay, D. M.,
and
P. K. Singh.
Superantigen-activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via interferon-gamma tumour necrosis factor-
. Inhibition of increased permeability, but not diminished secretory responses by transforming growth factor
2.
J. Immunol.
159:
2382-2390,
1997
29.
Merger, M.,
R. Borojevic,
D. Steele-Norwood,
and
K. Croitoru.
Enteropathy induced in mice by primary T cell stimulation in vivo is dependent on TCR
/
+ but not TCR
/
+ cells and is independent of CD4 or CD8 expression (Abstract).
Gastroenterology
112:
A1040,
1997.
30.
Ortho Multicenter Study Group.
A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
N. Engl. J. Med.
313:
337-341,
1985[Abstract].
31.
Powell, D. W.
Immunophysiology of intestinal electrolyte transport.
In: Handbook of Physiology. The Gastrointestinal System. Intestinal Absorption and Secretion. Bethesda, MD: Am. Physiol. Soc., 1991, sect. 6, vol. IV, chapt. 25, p. 591-641.
32.
Rahemtulla, A.,
T. M. Kündig,
A. Narendran,
M. F. Bachmann,
M. Julius,
C. J. Paige,
P. S. Ohashi,
R. M. Zinkernagel,
and
T. W. Mak.
Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice.
Eur. J. Immunol.
24:
2213-2218,
1994[Medline].
33.
Rodriguez, P.,
M. Heyman,
C. Candalh,
M. A. Blaton,
and
C. Bouchaud.
Tumour necrosis factor-
induces morphological and functional alterations of intestinal HT29 cl.19A cell monolayers.
Cytokine
7:
441-448,
1995[Medline].
34.
Schmitz, H.,
M. Fromm,
H. Bode,
P. Scholz,
E.-O. Riecken,
and
J. D. Schulzke.
Tumour necrosis factor-
-induced Cl
and K+ secretion in human distal colon driven by prostaglandin E2.
Am. J. Physiol.
271 (Gastrointest. Liver Physiol. 34):
G667-G674,
1996.
35.
Swain, M. G.,
A. Agro,
P. A. Blennerhassett,
A. M. Stanisz,
and
S. M. Collins.
Increased levels of substance P in the myenteric plexus of Trichinella-infected rats.
Gastroenterology
102:
1913-1919,
1992[Medline].
36.
Travis, S.,
and
I. Menzies.
Intestinal permeability: function assessment and significance.
Clin. Sci. (Colch.)
82:
471-488,
1992[Medline].
37.
Vallance, B. A.,
P. A. Blennerhassett,
and
S. M. Collins.
Increased intestinal muscle contractility and worm expulsion in nematode-infected mice.
Am. J. Physiol.
272 (Gastrointest. Liver Physiol. 35):
G321-G327,
1997
38.
Vallance, B. A.,
C. M. Hogaboam,
C. L. Addison,
J. Gauldie,
and
S. M. Collins.
Interleukin-4 gene transfer to the intestine causes inflammation and muscle dysfunction in mouse (Abstract).
Gastroenterology
110:
A1034,
1996.
39.
Vermillion, D. L.,
and
S. M. Collins.
Increased responsiveness of jejunal longitudinal muscle in Trichinella-infected rats.
Am. J. Physiol.
254 (Gastrointest. Liver Physiol. 17):
G124-G129,
1988
40.
Williamson, E.,
P. Garside,
J. A. Bradley,
I. A. R. More,
and
A. M. Mowat.
Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type autoimmune response and confers long term protection from disease.
J. Immunol.
159:
1208-1215,
1997[Abstract].
41.
Zund, G.,
J. L. Madara,
A. Dzus,
C. Awtrey,
and
S. P. Colgan.
Interleukin-4 and interleukin-13 differentially regulate epithelial chloride secretion.
J. Biol. Chem.
271:
7460-7464,
1996
This article has been cited by other articles:
![]() |
H. Akiho, W. I. Khan, A. Al-Kaabi, P. Blennerhassett, Y. Deng, and S. M Collins Cytokine modulation of muscarinic receptors in the murine intestine Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G250 - G255. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, N. Ameen, J. E. Melvin, and S. Vidyasagar Acute inflammation alters bicarbonate transport in mouse ileum J. Physiol., June 15, 2007; 581(3): 1221 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Akiho, P. Lovato, Y. Deng, P. J. M. Ceponis, P. Blennerhassett, and S. M. Collins Interleukin-4- and -13-induced hypercontractility of human intestinal muscle cells-implication for motility changes in Crohn's disease Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G609 - G615. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhou, C. Streutker, R. Borojevic, Y. Wang, and K. Croitoru IL-10 modulates intestinal damage and epithelial cell apoptosis in T cell-mediated enteropathy Am J Physiol Gastrointest Liver Physiol, September 1, 2004; 287(3): G599 - G604. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |